BioNeutra Global Corporation
BGACF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.02 | 0.10 | 0.02 |
| FCF Yield | 54.00% | 288.24% | -0.09% | 22.02% |
| EV / EBITDA | -19.83 | -4.78 | -11.22 | -8.21 |
| Quality | ||||
| ROIC | -99.40% | -74.41% | -40.19% | -38.10% |
| Gross Margin | 36.40% | 17.53% | 18.77% | 16.35% |
| Cash Conversion Ratio | -0.32 | -0.29 | -0.10 | -0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.59% | -17.81% | -25.80% | -13.85% |
| Free Cash Flow Growth | 4.66% | 11,224.56% | -100.42% | 188.56% |
| Safety | ||||
| Net Debt / EBITDA | -16.34 | -4.62 | -5.43 | -4.10 |
| Interest Coverage | -2.06 | -5.37 | -6.03 | -6.99 |
| Efficiency | ||||
| Inventory Turnover | 2.20 | 1.54 | 1.56 | 2.57 |
| Cash Conversion Cycle | -447.88 | -242.82 | -137.51 | -100.15 |